Our Pricing

Wegovy Safety Profile: What UK Patients Need to Know

Published on: June 03, 2026

Many patients ask is Wegovy safe UK prescription before starting treatment, and it's a question our clinical team at Cured Pharmacy addresses daily. Wegovy (semaglutide 2.4mg) is MHRA-licensed and supported by extensive clinical trial data showing both efficacy and a well-characterised safety profile when prescribed appropriately [1]. Our UK-registered prescribers assess every patient individually to ensure suitability, with transparent pricing from £79.00 and no NHS waiting lists.

Is Wegovy Safe? Clinical Evidence from STEP Trials

Wegovy's safety profile has been evaluated across five major STEP trials involving over 4,500 participants [1]. In the landmark STEP 1 trial, patients achieved an average 14.9% body weight reduction over 68 weeks, with the majority of adverse events classified as mild to moderate and transient [1]. The most commonly reported side effects were gastrointestinal — nausea, diarrhoea, and constipation — which typically diminished as patients adjusted to treatment.

Importantly, serious adverse events occurred at similar rates in both semaglutide and placebo groups, demonstrating that Wegovy does not introduce significant additional risk when prescribed to appropriate candidates [1]. The MHRA licensed Wegovy in 2023 after rigorous evaluation of this safety data, and NICE guidance now supports its use for weight management in adults with a BMI ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidities [2].

Our superintendent pharmacist Tarun Kumar (GPhC 2233073) emphasises that patient selection remains critical. Wegovy is contraindicated in individuals with personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease. Every consultation at Cured Pharmacy includes a thorough medical history review to identify any contraindications before prescribing.

Common Wegovy Side Effects and How to Manage Them

Understanding potential side effects helps patients feel confident starting treatment. In clinical trials, approximately 44% of participants experienced nausea, particularly during dose escalation phases [1]. However, Wegovy's gradual titration schedule — starting at 0.25mg weekly and increasing over 16 weeks to the maintenance dose of 2.4mg — significantly reduces the intensity of gastrointestinal symptoms.

Most patients find that side effects peak within 48 hours of each injection and resolve within 2-3 days. Eating smaller, more frequent meals, staying well-hydrated, and avoiding high-fat foods can further minimise discomfort. If symptoms persist or worsen, your prescriber may recommend maintaining your current dose for an additional month before escalating, or in some cases, stepping back to a lower dose temporarily.

When to Contact Your Prescriber

While most side effects are manageable, certain symptoms require immediate medical attention. Contact your prescriber or seek urgent care if you experience severe abdominal pain that doesn't resolve, persistent vomiting preventing fluid intake, visual changes, or signs of pancreatitis such as pain radiating to your back. Our clinical team at Cured Pharmacy remains available throughout your treatment journey to address concerns and adjust your care plan as needed.

Wegovy Safety: Who Should Not Use Semaglutide

Wegovy is not suitable for everyone, and responsible prescribing requires careful patient selection. Absolute contraindications include pregnancy or breastfeeding, personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and known hypersensitivity to semaglutide or any excipients [3]. Patients with a history of severe gastrointestinal disease, including gastroparesis or inflammatory bowel disease, may not be appropriate candidates.

Relative contraindications requiring additional caution include diabetic retinopathy, renal impairment, and concurrent use of other GLP-1 receptor agonists or insulin. Our UK prescribers assess these factors during your free online consultation, which takes under 3 minutes to complete. This thorough assessment ensures Wegovy is both safe and appropriate for your individual circumstances before any prescription is issued.

Age and BMI Requirements for Wegovy in the UK

Wegovy is licensed for adults aged 18 and over with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea [2]. These criteria align with NICE guidance and ensure treatment is targeted to those who will benefit most. Patients outside these parameters will not be prescribed Wegovy through our service, as patient safety remains our absolute priority.

How Wegovy Compares to Other Weight Loss Treatments

Wegovy belongs to the GLP-1 receptor agonist class, which works by mimicking a natural hormone that regulates appetite and food intake. Compared to older weight loss medications like orlistat, which blocks fat absorption, or Mysimba, which acts on brain reward pathways, GLP-1 treatments have demonstrated superior weight loss outcomes in head-to-head trials [4].

The STEP 8 trial directly compared semaglutide 2.4mg (Wegovy) with liraglutide 3.0mg (Saxenda), showing that Wegovy produced significantly greater weight reduction — 15.8% versus 6.4% at 68 weeks [4]. Newer dual-agonist treatments like Mounjaro (tirzepatide) have shown even higher average weight loss in some trials, but individual response varies considerably, and the best treatment depends on your medical history, tolerance, and prescriber recommendation.

Private Wegovy Prescription: How Cured Pharmacy Works

Accessing Wegovy through the NHS often involves lengthy waiting lists and strict eligibility criteria. At Cured Pharmacy, our private prescription service offers a streamlined alternative with transparent upfront pricing. Wegovy starts from £79.00, with the exact cost displayed before you begin your consultation — no hidden fees or surprise charges.

The process is straightforward: complete a free online clinical assessment in under 3 minutes, have your answers reviewed by a UK-registered prescriber, and if approved, receive your prescription dispensed by our GPhC-registered pharmacy (9012511). All medications are genuine UK-licensed products, delivered in 100% discreet packaging directly to your door. You'll also receive ongoing support from our clinical team throughout your treatment journey, with the option to message your prescriber at any point.

Transparent Pricing and Lowest Price Guarantee

We guarantee the lowest Wegovy prices in the UK. Our pricing model is simple: you see the cost before consultation, and there are no additional dispensing fees or mandatory subscription charges. If you find a lower price at another UK-registered pharmacy for the same product and dose, we'll match it. This commitment to transparency and affordability ensures you receive the treatment you need without financial uncertainty.

Long-Term Safety: What Happens After You Stop Wegovy

Clinical trial data demonstrates that Wegovy is safe for long-term use, with participants in extension studies maintaining treatment for over 2 years without new safety signals emerging [5]. However, many patients wonder about weight regain after discontinuation. The STEP 1 extension study showed that participants who stopped semaglutide regained approximately two-thirds of their lost weight within one year [5].

This doesn't indicate a safety concern, but rather highlights that obesity is a chronic condition requiring ongoing management. Wegovy is most effective when combined with sustainable lifestyle changes — improved nutrition, regular physical activity, and behavioural modifications. Our prescribers work with patients to develop comprehensive weight management plans that extend beyond medication alone, optimising both short-term results and long-term maintenance.

If you decide to discontinue Wegovy, there's no withdrawal syndrome or rebound effect beyond gradual weight regain. Some patients transition to maintenance doses, while others cycle treatment based on their goals and response. These decisions are made collaboratively with your prescriber, ensuring your treatment plan remains aligned with your health objectives.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
3. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
4. Rubino, D. M., et al. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA, 327(2), 138–150. https://doi.org/10.1001/jama.2021.23619 [accessed 13 August 2026]
5. Garvey, W. T., et al. (2023). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 29(10), 2492–2503. https://doi.org/10.1038/s41591-023-02502-2 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine and is subject to availability and prescriber approval based on individual clinical suitability.